An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation.

J T Holt, Robert L. Redner, Arthur W. Nienhuis

Molecular and Cellular Biology

Complementary OligomerMolecular RegulationImmunologyCell ProliferationCellular Physiology +16

Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation.

J T Holt, T. Venkat Gopal, A D Moulton, +1

Proceedings of the National Academy of Sciences

Transcriptional RegulationProtein ExpressionCell RegulationAntisense RnaHybrid Rna +11

Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice

Yasuhisa Matsui, Susan A. Halter, J T Holt, +2

Cell

Breast OncologyDevelopmental BiologyMammary Gland DevelopmentMammary GlandCell Proliferation +8

Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation.

Jennifer A. Pietenpol, J T Holt, Roland Stein, +1

Proceedings of the National Academy of Sciences

C-myc ExpressionImmunologyC-myc GeneCell ProliferationDermatology +16

Double-Strand Break Repair Deficiency and Radiation Sensitivity in BRCA2 Mutant Cancer Cells

Derek W. Abbott, J T Holt, Michael L. Freeman

JNCI Journal of the National Cancer Institute

Activation of the second promoter of the transforming growth factor-β1 gene by transforming growth factor-β1 and phorbol ester occurs through the same target sequences

S J Kim, Fabienne Denhez, Ki-Yong Kim, +3

Journal of Biological Chemistry

Molecular BiologyGrowth Factor-β1 GeneTranscriptional RegulationProtein ExpressionFirst Promoter +14

Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines.

Carl W. Rettenmier, Rosalba Sacca, Wayne L. Furman, +5

Journal of Clinical Investigation

Oncogenic AgentMedicineReceptor Tyrosine KinaseImmunologyColony-stimulating Factor-1 Receptor +12

Specific inhibition of c- <i>myc</i> protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes.

Annick Harel‐Bellan, Douglas K. Ferris, Michelle Vinocour, +2

The Journal of Immunology

Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.

David L. Tait, Patrice S. Obermiller, A R Hatmaker, +2

PubMed

ImmunologyImmunotherapyCancer BiologyTumor BiologyOvarian Cancer +14

A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer.

David L. Tait, Patrice S. Obermiller, S Redlin-Frazier, +6

PubMed

Gene TherapiesCancer-associated VirusMedicineImmunologyGynecology +11